Cheadle Royal Hospital, Cheadle, Cheshire, UK.
Curr Med Res Opin. 2011 Apr;27(4):745-9. doi: 10.1185/03007995.2011.554534. Epub 2011 Jan 27.
Agomelatine is a novel antidepressant with agonist activity at melatonin receptors (MT(1) and MT(2)), and antagonistic effects at the 5HT(2c) serotonin receptor.
This is a review of current evidence for clinical efficacy and safety, drawn from a literature review using Medline and PsycInfo in 2010 using search terms including agomelatine, melatonergic antidepressant and Valdoxan.
Agomelatine has antidepressant properties and from early on in its prescription agomelatine can improve sleep architecture and efficiency. Licensed for the treatment of depression in adults, other potential indications include seasonal affective disorder and anxiety disorders. Early controlled short-term studies of agomelatine as an antidepressant indicate good efficacy and tolerability. There are fewer side effects on sexual health than with SSRI antidepressants. No withdrawal or discontinuation syndrome has yet been observed. Agomelatine is contraindicated in patients with impaired liver function and repeated liver function tests are suggested during prescription.
Agomelatine is a useful and novel addition to the range of avialble antidepressants. Longer term post-marketing studies as to the effects of chronic exposure are required.
阿戈美拉汀是一种新型抗抑郁药，对褪黑素受体（MT1 和 MT2）具有激动活性，对 5HT2c 血清素受体具有拮抗作用。
这是对当前临床疗效和安全性证据的综述，使用 Medline 和 PsycInfo 在 2010 年进行了文献回顾，使用的搜索词包括阿戈美拉汀、褪黑素能抗抑郁药和 Valdoxan。
阿戈美拉汀具有抗抑郁作用，从开始处方阿戈美拉汀起，它就可以改善睡眠结构和效率。阿戈美拉汀获准用于治疗成年人的抑郁症，其他潜在适应症包括季节性情感障碍和焦虑症。早期关于阿戈美拉汀作为抗抑郁药的对照短期研究表明其疗效和耐受性良好。与 SSRI 抗抑郁药相比，它对性健康的副作用较少。尚未观察到停药或停药综合征。阿戈美拉汀禁用于肝功能受损的患者，建议在处方期间反复进行肝功能检查。
阿戈美拉汀是一种有用的新型抗抑郁药，可供选择。需要进行更长期的上市后研究，以了解慢性暴露的影响。
